Table 1 Cases of acute myeloid leukemia with sole trisomy 6 and their laboratory findings
Case | Diagnosis | Karyotype | Survival (months) | Age (years) | Sex | WBC* | Hb** | PLT*** | References | Country |
|---|---|---|---|---|---|---|---|---|---|---|
Adult cases | ||||||||||
1 | AML-NS | NA | 36 | 74 | M | NA | NA | NA | Panani et al. [20] | Greece |
2 | AML-M4 | 47,XX, + 6[8/18] | 1 | 50 | F | NA | NA | NA | Testa et al. [21] | USA |
3 | AML-M5 | 47,XX,+6[58/58] | 4 | 24 | F | NA | NA | NA | Weh et al. [22] | Germany |
4 | AML-M2 | 47,XX,+6[2/7] | NA | 81 | M | NA | NA | NA | Chan et al. [23] | Hong Kong |
5 | AML-M2 | 47,XX,+6[3/8] | NA | NA | F | NA | NA | NA | Berger et al. [24] | France |
6 | AML (M2) | 47,XY,+6[15/21] | > 1 | 55 | M | NA | NA | NA | UKCCG [25] | U.K. |
7 | AML (M5a) | 47,XX,+6[17/17] | > 15 | 55 | M | NA | NA | NA | UKCCG [25] | U.K. |
8 | AML-NS | 47,XX,+6[2/?] | 22 | 37 | F | NA | NA | NA | UKCCG [25] | U.K. |
9 | AML-M2 | 47,XX,+6[3/9]/46,XX[6/)9] | 3 | 63 | F | 4.8 | 13.5 | 6 | Jonveaux et al. [18] | France |
10 | AML-M2 | 47,XX,+6[17/19]/46,XX[2/19] | 1+ | 28 | F | 4 | 11 | 53 | Jonveaux et al. [18] | France |
11 | AML-M4 | 47,XX,+6[19/30]/46,XX[11/30] | 22 | 66 | F | 2.6 | 8.1 | 51 | Mohamed et al. [11] | USA |
12 | AML-M1 | 47,XX,+6[30/30] | 1 | 74 | M | 29.4 | 9.3 | 26 | Mohamed et al. [11] | USA |
13 | AML-M1 | 47,XY,+6[20/20] | 4 | 22 | M | 4.4 | 12.5 | 238 | Mohamed et al. [11] | USA |
14 | AML-M1 | 47,XY,+6[7/20]/46,XY[13/20] | 10 | 40 | M | 86.5 | 11.1 | 63 | Mohamed et al. [11] | USA |
15 | AML-MRC | 47,XX,+6[39/40]/46,XX[1/40] | > 47 | 37 | F | 5.1 | 12.2 | 11 | Mohamed et al. [11] | USA |
16 | AML-NS | 47,XX, +6[8/23]/46,XX[15/23] | 27 | 41 | F | NA | NA | NA | De Souza et al. [26] | Brazil |
17 | AML-NS | 47,XX,+6 | NA | NA | F | NA | NA | NA | Kerndrup and Kjeldsen [27] | Denmark |
18 | AML-NS | 47,XX,+6 [11] | NA | 61 | F | NA | NA | NA | Beyer et al. [28] | Switzerland |
19 | AML-M1 | 47,XX,+6[20] | 23 | 51 | M | 20.77 | 13.5 | 4 | Yu et al. [4] | South Korea |
20 | AML-M2 | 47,XX,+6[20] | > 58 | 25 | F | 82.94 | 8 | 109 | Yu et al. [4] | South Korea |
21 | AML-M4 | 47,XX,+6[4/20]/46,XX,[16/20] | 3 | 82 | M | 5.08 | 6.4 | 21 | Yu et al. [4] | South Korea |
22 | AML-M7 | 47,XX,+6[12/20]/46,XX[8/20] | 1 | 21 | F | 56.3 | 5.4 | 85 | Gupta et al. [10] | India |
23 | AML-NS | 47,XX,+6 | 1 | 50 | F | NR | 8.5 | 11 | Aydin et al. [29] | Turkey |
24 | AML-M5 | 47,XY,+6 | 3 | 75 | M | 103.8 | 7.3 | 80 | Manabe et al. [12] | Japan |
Pediatric cases | ||||||||||
25 | AML-NS | 47,XY,+6 | NA | 11 | M | NA | NA | NA | Philip et al. [13] | Denmark |
26 | AML-NS | 47,XX,+6[8] | 27 | 8 | F | 99 | NA | NA | Benedict et al. [14] | USA |
27 | AML-(M3) | 47,XY,+6 | > 7 | 8 | M | NA | NA | NA | UKCCG [25] | U.K. |
28 | AML-M7 | 47,XX,+6[9/20]/46,XX[11/20] | NA | 1 | M | 16.4 | 7.6 | 6 | McCullough et al. [15] | Ireland |
29 | AML-NS | 47,XX,+6 | 18 | 8 | F | NA | NA | NA | Koh et al. [19] | South Korea |
30 | AML-M4 | 47,XX,+6[12/15]/46,XX[3/15] | 1 | 14 | M | 244 | 5.7 | 52 | Present report | |